Tools
Tools
Steverding, Dietmar and Tyler, Kevin M. 
ORCID: https://orcid.org/0000-0002-0647-8158
(2005)
Novel antitrypanosomal agents.
Expert Opinion on Investigational Drugs, 14 (8).
pp. 939-955.
ISSN 1354-3784
Abstract
Trypanosomes are the causative agents of Chagas' disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago. In addition, these drugs display undesirable toxic side effects and the emergence of drug-resistant trypanosomes has been reported. Therefore, the development of new drugs in the treatment of Chagas' disease and sleeping sickness is urgently required. This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy. Particular emphasis is placed on those agents showing promising, selective antitrypanosomal activity.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health Faculty of Medicine and Health Sciences > Research Groups > Pathogen Biology Group |
| Depositing User: | EPrints Services |
| Date Deposited: | 25 Nov 2010 11:08 |
| Last Modified: | 24 Sep 2024 10:00 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/11503 |
| DOI: | 10.1517/13543784.14.8.939 |
Actions (login required)
 |
View Item |